MENU
IMUX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Immunic (IMUX) Ownership - Who owns Immunic?

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

Profile

Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
85.83M
P/E Ratio
N/A
Total Cash
55.31M
Projected Growth
N/A
Total Debt
979K
Revenue
N/A
Risk (Beta)
1.41
Dividend Yield
N/A
Total Cash/Share
0.56
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

IMUX
Capitalization
85.8M
P/E Ratio
N/A
Risk (Beta)
1.41
Dividend Yield
N/A
Total Cash
55.3M
Total Cash/Share
0.56
Total Debt
979K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
33.9M
P/B Ratio
2.53
Cash Flow
N/A
Earnings
-0.94
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
9K
Current Ratio
2.19
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-105.1M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-137.69
Shares Held By Institutions
128M
Shares Outstanding - Current
98.7M
Total Liabilities
27.5M
Total Volume MTD
N/A
Value
1
Gain YTD
-13.000
View a ticker or compare two or three
IMUX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. IMUX showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals and oral therapies for the treatment of chronic inflammatory and autoimmune diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
1200 Avenue of the Americas
Phone
+1 332 255-9818
Employees
77
Web
https://www.imux.com